anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product [see Contraindications (4.1, 4.2)].

Patients should be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions or by inadvertent contact with the dropper tip [see Warnings and Precautions (5.10)]. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.

Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.

Patients should be advised that brimonidine tartrate/timolol maleate ophthalmic solution contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of brimonidine tartrate/timolol maleate ophthalmic solution.

As with other similar medications, brimonidine tartrate/timolol maleate ophthalmic solution may cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.

July 2021
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. As with any effective diuretic, electrolyte depletion may occur during LASIX therapy, especially in patients receiving higher doses and a restricted salt intake. Hypokalemia may develop with LASIX, especially with brisk diuresis, inadequate oral electrolyte intake, when cirrhosis is present, or during concomitant use of corticosteroids, ACTH, licorice in large amounts, or prolonged use of laxatives. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially myocardial effects.

All patients receiving LASIX therapy should be observed for these signs or symptoms of fluid or electrolyte imbalance (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia or hypocalcemia): dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting. Increases in blood glucose and alterations in glucose tolerance tests (with abnormalities of the fasting and 2-hour postprandial sugar) have been observed, and rarely, precipitation of diabetes mellitus has been reported.

In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. Thus, these patients require careful monitoring, especially during the initial stages of treatment.

In patients at high risk for radiocontrast nephropathy, LASIX can lead to a higher incidence of deterioration in renal function after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrast.

In patients with hypoproteinemia (e.g., associated with nephrotic syndrome), the effect of LASIX may be weakened and its ototoxicity potentiated.

Asymptomatic hyperuricemia can occur and gout may rarely be precipitated.

Patients allergic to sulfonamides may also be allergic to LASIX. The possibility exists of exacerbation or activation of systemic lupus erythematosus.

As with many other drugs, patients should be observed regularly for the possible occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactions.
BACKGROUND AND AIM: The occurrence of brain lesions in preterm infants is common and can result in lasting disabilities. To prevent these and to safeguard the brain through therapeutic measures or neuroprotective treatments, it is important to identify cerebral ischaemia/hypoxia and haemorrhage at an early stage. For this purpose, we have successfully developed a cutting-edge time-domain near-infrared optical tomography (TD-NIROT) system, which offers diagnostic imaging for neonatal brain oxygenation. Our objective is to validate the effectiveness of the TD-NIROT in detecting deep ischaemia/hypoxia and haemorrhages through phantom experiments.
METHODS: Spherical silicone phantoms were fabricated to replicate the head of preterm infant. To simulate the lesions, we made two head phantoms and embedded small inclusions mimicking ischaemia and haemorrhage at the depth of 30 mm. Additionally, a spherical interface was constructed to connect the spherical phantom to the imaging system, allowing us to collect time-domain data. Following the data acquisition, we proceeded with image reconstruction. Dice similarity was used as an indicator of the accuracy and similarity between the reconstructed images and the ground truth.
RESULTS AND DISCUSSION: The resulting images exhibited an accurate location of haemorrhage and detected the ischaemia with a slightly shifted position with Dice similarity of 0.47 and 0.27.
CONCLUSION: Our experiment validates the capability of our TD-NIROT system in successfully detecting deep haemorrhages and ischaemia within the phantom model. The achieved results suggest a promising level of accuracy in the imaging process. These findings are encouraging to continue this work to ultimately achieve clinical application of the TD-NIROT system in diagnosing and monitoring neonatal brain injuries.
OBJECTIVE: Mucosal T cells play a major role in inflammatory bowel disease (IBD). However, their immunometabolism during intestinal inflammation is poorly understood. Due to its impact on cellular metabolism and proinflammatory immune cell function, we here focus on the enzyme ATP citrate lyase (ACLY) in mucosal T cell immunometabolism and its relevance for IBD.
DESIGN: ACLY expression and its immunometabolic impact on colitogenic T cell function were analysed in mucosal T cells from patients with IBD and in two experimental colitis models.
RESULTS: ACLY was markedly expressed in colon tissue under steady-state conditions but was significantly downregulated in lamina propria mononuclear cells in experimental dextran sodium sulfate-induced colitis and in CD4+ and to a lesser extent in CD8+ T cells infiltrating the inflamed gut in patients with IBD. ACLY-deficient CD4+ T cells showed an impaired capacity to induce intestinal inflammation in a transfer colitis model as compared with wild-type T cells. Assessment of T cell immunometabolism revealed that ACLY deficiency dampened the production of IBD-relevant cytokines and impaired glycolytic ATP production but enriched metabolites involved in the biosynthesis of phospholipids and phosphatidylcholine. Interestingly, the short-chain fatty acid butyrate was identified as a potent suppressor of ACLY expression in T cells, while IL-36α and resolvin E1 induced ACLY levels. In a translational approach, in vivo administration of the butyrate prodrug tributyrin downregulated mucosal infiltration of ACLYhigh CD4+ T cells and ameliorated chronic colitis.
CONCLUSION: ACLY controls mucosal T cell immunometabolism and experimental colitis. Therapeutic modulation of ACLY expression in T cells emerges as a novel strategy to promote the resolution of intestinal inflammation.
Participants aged 65 to 75 years will receive BIIB113, orally, QD, on Days 1 to 14 of Part B of the study. The calculated dose level will be adaptive by design based on review of the safety, tolerability, and PK data from Cohorts 1 to 7.
The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10\^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
The present invention relates to a method for monitoring hemostasis in a subject who may or may not be under anticoagulant therapy, comprising the steps of: a) providing a blood sample from said individual comprising a complex between a Factor Xa (FXa) or a modified catalytically active FXa, and a-2 macroglobulin (a2M); b) determining clot formation in the sample from step a) to obtain a test value; and c) comparing the test value from step b) to a reference value, wherein a variation of said test value over said reference is indicative of hemostasis in said subject. In one embodiment, said complex can be used for discriminating a defect in haemostasis due to a non-vitamin K antagonist (non-VKA) anticoagulant therapy from a coagulopathy or a VKA therapy in said subject. Said complex can also be used for preventing or reducing bleeding in a subject undergoing anticoagulant therapy; and/or for binding and inhibiting an exogenously administered anticoagulant in said subject. Pharmaceutical compositions and kits are also disclosed, as well as a method for preparing a complex. The modified catalytically active FXa can be a Gla-domain deficient FXa (Gla-deficient FXa) or a Gla-domainless FXa (GDFXa). The Inventors have shown by in vitro and in vivo (mice) that the novel antidote as described here provides a differential diagnosis in a rapid and sensitive manner, including in Whole Blood (WB) samples, or a fraction thereof.
BACKGROUND: Obesity represents an epidemic of rising numbers worldwide year after year. In the Orthopedic field, obesity is one of the major causes leading to osteoarthritis needing Total Joint Arthroplasty (TJA). Still, contextually, it represents one of the most significant risk factors for joint replacement complications and failures. So, bariatric Surgery (BS) is becoming a valuable option for weight control and mitigating obesity-related risk factors. This review of the literature and meta-analysis aims to evaluate periprosthetic joint infections (PJI) and surgical site infections (SSI) rates in patients who underwent TKA after BS compared to obese patients without BS.
METHODS: Systematic review was performed according to Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines up to October 2023. We included longitudinal studies comparing obese patients who underwent total knee arthroplasty after bariatric surgery (study group) and obese patients who underwent TKA (control group). The surgical site infection and Periprosthetic joint infection rate were compared among groups using a meta-analytical approach.
RESULTS: The online database and references investigation identified one hundred and twenty-five studies. PJI rate differed significantly among groups, (z = -21.8928, p < 0.0001), with a lower risk in the BS group (z = -10.3114, p < 0.0001), for SSI, instead, not statistically significance were recorded (z = -0.6784, p = 0.4975).
CONCLUSIONS: The current Literature suggests that Bariatric Surgery can reduce infectious complications in TKA, leading to better outcomes and less related costs treating of knee osteoarthritis in obese patients.
<P>PROBLEM TO BE SOLVED: To provide a means for reducing transient irritation in a preparation of ascorbic acids in high concentration.  <P>SOLUTION: The external preparation for the skin contains (1) 4-6 wt.% one or more kinds selected from ascorbic acid, a derivative thereof and a salt thereof, and (2) 0.4-1 wt.% buffer. Phosphoric acid and a salt thereof are used as the buffer, and the pH is regulated so as to be 8-9. An essence of a plant of Tiliaceae such as Tilia europaea, a plant of Asteraceae such as Calendula officinalis and Arctium Lappa, or a plant of Rosaceae such as Sanguisorba officinalis can be contained as an antiinflammatory component. An essence of a plant of Betulaceae such as Betula japonica x, or an essence of a plant of Moraceae such as Morus bombycis Koidz is suitably contained as other galenical essences.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Nanocages are formed by etching nanocubes. The nanocubes are added to an aqueous system having an amphiphilic lipid dissolved in an organic solvent (e.g. a hydrophobic alcohol) to form reverse micelles. As the water evaporates the micelles shrink as etching of the flat surface of the nanocubes occurs. In this fashion hollow nanocages are produced. In one embodiment, the nanocage is covalently attached to a polymer shell (e.g. a dextran shell).
The lingual surfaces of the anterior six teeth, including the canines, in the maxilla and mandible were roughened by the application of 37.5% phosphoric acid for 30 seconds. Since the applied composite system is one-stage, no additional bond application was done. Fixed lingual retainer wire was applied with a Bis-GMA-free flowable composite adhesive with 60 seconds exposure for 10 seconds for each tooth.
Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposited at sites of diabetic tissue damage. Glycated albumin inhibits the growth of cells. Treatment with monoclonal anti-glycated albumin antibody reverses the growth inhibition caused by glycated albumin. In addition, glycated albumin stimulates the production of type IV collagen by kidney cells. Antibodies which bind to glycated albumin prevent the stimulation of type IV collagen production.
In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
PROBLEM TO BE SOLVED: To provide a method for producing the subject composition, capable of dissolving a polymer fed in powdery state into water or the like without increasing viscosity and improving handleability or the like by mixing a specific emulsion with a specific aqueous polymer solution. SOLUTION: An oil (e.g. light liquid paraffin) and water are emulsified by using a surfactant (e.g. ethyl lanolin sulfate fatty acid aminopropylethyldimethylammonium) to afford an emulsion (A). Powdery cationic polymer (e.g. cationized dextrin) and powdery anionic polymer (e.g. polyacrylic acid) are dissolved in water to afford a polymer aqueous solution (B). The component A is mixed with the component B in a mixed ratio of (1/9) to (9/1) to provide the objective composition. The example of the composition includes shampoo, rinse, hair get, a hair dyeing agent, a depilatory or a permanent waving agent. The dosage form includes cream, gel, liquid or foam.
OBJECTIVE: Sepsis constitutes a significant global healthcare burden. Studies suggest a correlation between educational attainment and the likelihood of developing sepsis. Our goal was to utilize Mendelian randomization (MR) in order to examine the causal connection between educational achievement (EA) and sepsis, while measuring the mediating impacts of adjustable variables.
METHODS: We collected statistical data summarizing educational achievement (EA), mediators, and sepsis from genome-wide association studies (GWAS). Employing a two-sample Mendelian randomization (MR) approach, we calculated the causal impact of education on sepsis. Following this, we performed multivariable MR analyses to assess the mediation proportions of various mediators, including body mass index (BMI), smoking, omega-3 fatty acids, and apolipoprotein A-I(ApoA-I).
RESULTS: Genetic prediction of 1-SD (4.2 years) increase in educational attainment (EA) was negatively correlated with sepsis risk (OR = 0.83, 95% CI 0.71 to 0.96). Among the four identified mediators, ranked proportionally, they including BMI (38.8%), smoking (36.5%), ApoA-I (6.3%) and omega-3 (3.7%). These findings remained robust across a variety of sensitivity analyses.
CONCLUSION: The findings of this study provided evidence for the potential preventive impact of EA on sepsis, which may be influenced by factors including and metabolic traits and smoking. Enhancing interventions targeting these factors may contribute to reducing the burden of sepsis.
Pulsatile tinnitus (PT) can be a debilitating condition characterized by rhythmic, heartbeat-synchronous sounds, which can severely impact patients' quality of life. Understanding the neuroanatomical changes in PT patients may provide critical insights into the impacts of this condition. This study aimed to investigate potential differences in cortical and subcortical brain volume between adults with PT and age-matched controls (60 to 70 years of age). A retrospective, cross-sectional analysis of imaging and medical records was conducted, with data collected from January 2015 to December 2021. The study was conducted in a tertiary referral center with a specialized tinnitus clinic. A total of 135 adults diagnosed with PT and 135 age-matched controls were included. All participants were screened for PT and relevant medical history, with consecutive sampling used for selection. Cortical and subcortical brain volume differences between PT patients and controls were measured using Freesurfer. PT patients (n = 79, after exclusion of patients with inadequate imaging data) exhibited significant decreases in cortical thickness in the anterior cingulate and entorhinal cortex, and decreased volume in the left putamen, compared to age-matched controls (n = 135). PT patients also demonstrated significant increased volume in frontal and occipital lobe structures, the cerebellum, hippocampi, and ventral pallidum. In conclusion, our findings suggest that individuals with PT may have structural differences in brain regions related to auditory processing, and depression, which provides additional evidence of the psychiatric sequalae of PT. These findings demonstrate that there are neuroanatomical alterations in patients with PT, emphasizing the value in evaluating and treating this disease to prevent these neuroanatomical differences from developing.
A compound and method for treating tinea pedis. An antifungal agent, such as melaleuca alternifolia extract oil, is added to the ingredients of soap in a concentration that is great enough to treat tinea pedis when the skin is washed with the soap. As a result, a person is effectively applying a preventative treatment of the antifungal agent each time that person baths with the soap. The duration of the treatment is regulated by selectively altering the size and/or amount of soap. Other ingredients can also be added to the soap to increase the effectiveness of the antifungal agent. Furthermore, fragrance can be added to the soap to mask any unpleasant odor that may be associated with the antifungal agent or the other active ingredients.
Polyuria-polydipsia syndrome is a frequent symptom in pediatrics, primarily attributed to diabetes mellitus. In the context of diabetes insipidus, this syndrome can stem from central or nephrogenic factors. Sjögren's syndrome, an uncommon autoimmune disease in children, can affect multiple organs. Kidney involvement as described in adults is usually related to glomerular or tubular impairment, often linked to distal tubular acidosis. As a kidney involvement during childhood, Sjögren's syndrome has rarely been reported. Hereby, we present the case of Sjögren's syndrome revealed by polyuria-polydipsia syndrome in a 10-year-old boy.
To achieve maximum contraceptive effectiveness, DOLISHALE (levonorgestrel and ethinyl estradiol tablets) must be taken exactly as directed and at intervals not exceeding 24 hours. The possibility of ovulation and conception prior to initiation of medication should be considered. Women who do not wish to become pregnant after discontinuation should be advised to immediately use another method of birth control. The dosage of DOLISHALE is one green tablet daily without any tablet-free interval. 

It is recommended that DOLISHALE tablets be taken at the same time each day. 

Initiation of Therapy 

Instructions for beginning DOLISHALE are provided in Table 4 below.

Table 4

If spotting or unscheduled bleeding occurs, the patient is instructed to continue on the same regimen. This type of bleeding is usually transient and without significance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her health care professional. The possibility of ovulation increases with each successive day that scheduled green tablets are missed. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day later than she should have), the probability of pregnancy should be considered. Hormonal contraception must be discontinued if pregnancy is confirmed. 

The risk of pregnancy increases with each tablet missed. For additional patient instructions regarding missed tablets, see the WHAT TO DO IF YOU MISS PILLS section in the DETAILED PATIENT LABELING below. 

DOLISHALE may be initiated no earlier than day 28 postpartum in the nonlactating mother or after a second-trimester abortion due to the increased risk for thromboembolism (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS concerning thromboembolic disease). The patient should be advised to use a nonhormonal back-up method for the first 7 days of tablet-taking. However, if intercourse has already occurred, pregnancy should be excluded before the start of combined oral contraceptive use or the patient must wait for her first menstrual period. 

In the case of first-trimester abortion, if the patient starts DOLISHALE immediately, additional contraceptive measures are not needed.
Chronic liver disease (CLD) is a persistent public health burden, with over one billion cases reported worldwide. In most cases, the progression of CLD is slow and undulating with end-stage liver disease developing at variable time points depending on the underlying etiology of the disease. The concept of reversibility or halting progression to end stage liver disease is recent and various medications are in the pipeline which influence the progression of CLD. Non-invasive tests for monitoring of CLD may have the potential to avoid the morbidity and mortality related to invasive procedures. However, their applicability and validation in pediatrics requires further development and a coordinated effort by large pediatric liver centres. Recent advances in metabolomics and modern molecular technologies have led to an understanding of the interaction between gut microbiome liver axis and gut dysbiosis contributing to liver diseases. In the future, modifying the gut microbiome has the potential to change the outcome and significantly reduce the morbidity associated with CLD. This article focuses on newer modalities and concepts in the management of CLD, which may help develop strategies to prevent its progression to end-stage liver disease and associated morbidity/mortality.